Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Autor: Richardson, Paul G, Oriol, Albert, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darrell, Facon, Thierry, San Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Semochkin, Sergey, Schey, Steve, Yu, Xin, Doerr, Thomas, Bensmaine, Amine, Biyukov, Tsvetan, Peluso, Teresa, Zaki, Mohamed, Anderson, Kenneth, Dimopoulos, Meletios, OPTIMISMM trial investigators, Abildgaard N, Adler H, Altuntas F, Akay OM, Amin B, Anagnostopoulos A, Anderson L, Anttila P, Araujo C, Arce-Lara C, Aydin Y, Basu S, Battini R, Beeker T, Benboubker L, Ben-Yehuda D, Bladé J, Blau IW, Boccia R, Burke L, Byeff P, Cascavilla N, Cavo M, Chantry A, Charles Y, Chaudhry A, Corso A, Coyne M, De Arriba F, Delimpasi S, Desjardins P, Dhakal B, Di Bartolomeo P, Di Raimondo F, Dürig J, Engelhardt M, Escoffre-Barbe M, Esteves G, Flogegard M, Gabrail N, Gamberi B, Garrison M, Gay J, Gisslinger H, Goldschmidt H, Goncalves C, Gressot L, Grosicki S, Hanna W, Hayden P, Henriques Bernardo MM, Hermann R, Holden V, Honkalehto K, Huben M, Huffman J, Hunter H, Hus M, Jagasia M, Jagganath S, Janakiram M, Jaiyesimi I, Jenner M, João C, Johnson P, Jurcyszyn A, Kalayoğlu Beşişik S, Kambhampati S, Kanate A, Karadoğan I, Khojasteh A, Kirkel D, Komarnicki M, Krauth MT, Kuriakose P, Larocca A, Lauri B, Leleu X, Lucio P, Luppi M, Mangiacavalli S, Mariette C, Matsue K, Mellqvist UH, Mendeleeva L, Meshad M, Miller C, Mohrbacher A, Moreau P, Morelli AM, Müldür E, Naassan A, Nahi H, Nair R, O'Dwyer M, Öngören Aydin S, Openshaw T, O'Rourke T, Osswald M, Overton L, Pati A, Pavic M, Pegourie B, Pehlivan M, Pierola AA, Plesner T, Pluta A, Rabin N, Ramasamy K, Rambaldi A, Rodriguez P, Röllig C, Rosenblatt J, Rosenbluth J, Salomo M, Samoylova O, Sastre Moral J, Sati H, Selleri C, Shafeek S, Shinagawa A, Sleckman B, Smith C, Sonmez M, Stone C, Streetly M, Suzuki K, Taetle R, Tafuri A, Takezako N, Teke HÜ, Vapaatalo M, Vassilopoulos G, Verma A, Vidito S, Viterbo L, Vural F, Wang XS, Yağci M, Yee A.

Publikováno v: LANCET ONCOLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
BASE-Bielefeld Academic Search Engine
Lancet Oncology, 20(6), 781-794. Lancet Publishing Group
Richardson, P G, Oriol, A, Beksac, M, Liberati, A M, Galli, M, Schjesvold, F, Lindsay, J, Weisel, K, White, D, Facon, T, San Miguel, J, Sunami, K, O'Gorman, P, Sonneveld, P, Robak, P, Semochkin, S, Schey, S, Yu, X, Doerr, T, Bensmaine, A, Biyukov, T, Peluso, T, Zaki, M, Anderson, K, Dimopoulos, M, OPTIMISMM trial investigators & Abildgaard, N 2019, ' Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM) : a randomised, open-label, phase 3 trial ', The Lancet Oncology, vol. 20, no. 6, pp. 781-794 . https://doi.org/10.1016/S1470-2045(19)30152-4

Background As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has show

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cccf2220a5bc187bbb4a4254d3d0f52
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4189

P1178: THE APPLICABILITY OF PROGNOSTIC MODELS UNDER RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A COMPARISON WITH R‐CHOP.

Autor: Vassilakopoulos, Theodoros, Ferhanoglu, B, Horowitz, Na, Apostolidis, J, Mellios, Z, Piperidou, Alexia, Kaynar, L, Zektser, M, Giotasmater, A, Hospital, Dei, Malta, Msida, Symeonidis, A, Kalpadakis, C, Agathocleous, A, Akay, Om, Sayyed, A, Atalar, Sc, Katodritou, E, Leonidopoulou, T, Papageorgiou, Sg

Publikováno v: HemaSphere; 2023 Supplement 3, Vol. 7, p1-2, 2p

with chronic myeloid leukemia: A retrospective multicenter study

Autor: Korkmaz, S, Dal, MS, Berber, I, Sahin, DG, Dogu, MH, Ayyildiz, O, Nizam, I, Albayrak, M, Esen, R, Namdaroglu, S, Sencan, M, Akay, OM, Hacioglu, S, Yildirim, R, Eser, A, Tombak, A, Pala, C, Ilhan, O

AimsWe aimed to investigate whether older age leads to limitations in the starting dose of imatinib in daily treatment of chronic myeloid leukemia, and to determine the compliance of elderly patients with tyrosine kinase inhibitors (TKI) therapy. Met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::09a086877b6dc16a849cec4725ab9705
http://acikerisim.pau.edu.tr:8080/xmlui/handle/11499/22451

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.